New combo therapy shows promise for Tough-to-Treat prostate cancer
NCT ID NCT03674814
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 21 times
Summary
This early-stage study tested a new drug combination for men with advanced prostate cancer that no longer responds to standard hormone therapy. The trial included 42 participants and aimed to see if adding relacorilant to enzalutamide is safe and can help control the disease. Researchers measured side effects, drug levels, and signs of anti-cancer activity like PSA levels and tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.